Search Within

Helena Alexandra Yu

Formats
  1. Meeting Abstract (162)
  2. Journal Article (109)
  3. Editorial (9)
  4. Review (7)
  5. Book Section (2)
  6. Conference Paper (1)
  7. Correspondence (1)
Groups
  1. Department of Medicine (291)
  2. Solid Tumor Oncology Division (291)
  3. Thoracic Oncology (291)
  4. GSK Faculty (121)
  5. Department of Pathology and Laboratory Medicine (103)
  6. Human Oncology and Pathogenesis Program (102)

More Groups

People
  1. Gregory Riely (108)
  2. Mark Kris (95)
  3. Marc Ladanyi (71)
  4. Charles Rudin (58)
  5. Maria Arcila (56)
  6. Alexander Drilon (36)

More People

Years
  1. 2025 (20)
  2. 2024 (28)
  3. 2023 (30)
  4. 2022 (33)
  5. 2021 (30)
  6. 2020 (15)

More Years

Publications
  1. Journal of Clinical Oncology (75)
  2. Journal of Thoracic Oncology (63)
  3. Annals of Oncology (27)
  4. Clinical Cancer Research (18)
  5. International Journal of Radiation Oncology, Biology, Physics (14)
  6. Cancer Discovery (9)

More Publications

Publishers
  1. Elsevier Inc. (86)
  2. American Society of Clinical Oncology (84)
  3. American Association for Cancer Research (31)
  4. Oxford University Press (31)
  5. Nature Publishing Group (12)
  6. Elsevier Science, Inc. (7)

More Publishers

Results (291)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Multi-modality AI predictor of lung cancer immunotherapy treatment response of durable response (DR)
    Meeting Abstract

    Jiang, J.; Yu, H.; Gomez, D.; Veeraraghavan, H.
    Radiotherapy and Oncology (2025)

    Fulltext@MSK | Save
  • Overall survival in EGFR-mutant advanced NSCLC treated with first-line osimertinib: A cohort study integrating clinical and biomarker data in the United States
    Journal Article

    Sabari, J. K.; Yu, H. A.; Mahadevia, P. J.; Liu, Y.; Demirdjian, L.; Chen, Y. H.; Wang, X.; Passaro, A.
    Journal of Thoracic Oncology (2025)

    Fulltext@MSK | Save
  • Zipalertinib in patients with epidermal growth factor receptor exon 20 insertion-positive non-small cell lung cancer previously treated with platinum-based chemotherapy with or without amivantamab
    Journal Article

    Piotrowska, Z.; Passaro, A.; Nguyen, D.; Ruiter, G.; Soo, R. A.; Lee, V. H. F.; Velcheti, V.; Tan, D. S. W.; Lee, S. H.; Kim, S. H.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Real-world deployment of a fine-tuned pathology foundation model for lung cancer biomarker detection
    Journal Article

    Campanella, G.; Kumar, N.; Nanda, S.; Singi, S.; Fluder, E.; Kwan, R.; Muehlstedt, S.; Pfarr, N.; Schüffler, P. J.; Häggström, I.; more...
    Nature Medicine (2025)

    Fulltext@MSK | Save
  • Identifying the genomic landscape of EGFR-mutant lung cancers with central nervous system metastases
    Journal Article

    Wilcox, J. A.; Jeng, M. Y.; Tischfield, S.; Sui, J. S. Y.; Nemirovsky, D.; Heller, G.; Choudhury, N. J.; Ross, J. S.; Rudin, C. M.; Riely, G. J.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • Intrathecal deferoxamine in patients with leptomeningeal metastases: Phase 1a analysis
    Meeting Abstract

    Wilcox, J.; Reiner, A. S.; Young, R. J.; Emadi-Paramkouhi, L.; Weill, B.; Myers, L.; Tulca, Y.; Gonzalez, A.; Estrera, R.; Osei-Gyening, I.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Responsiveness of different MET tumour alterations to type I and type II MET inhibitors
    Journal Article

    Murciano-Goroff, Y. R.; Foglizzo, V.; Chang, J.; Rekhtman, N.; Sisk, A. E.; Gibson, J.; Judka, L.; Clemens, K.; Roa, P.; Ahmed, S. S.; more...
    Clinical and Translational Medicine (2025)

    Fulltext@MSK | Save
  • Management of EGFR-variant and ALK-positive non-small cell lung cancer brain metastasis
    Editorial

    Pike, L. R. G.; Yu, H.; Rusthoven, C. G.
    JAMA Oncology (2025)

    Fulltext@MSK | Save
  • ORCHARD: Osimertinib plus necitumumab in patients with epidermal growth factor receptor–mutated advanced non–small cell lung cancer with a secondary epidermal growth factor receptor alteration whose disease had progressed on first-line osimertinib
    Journal Article

    Riess, J. W.; de Langen, A. J.; Ponce, S.; Goldberg, S. B.; Piotrowska, Z.; Goldman, J. W.; Le, X.; Cho, B. C.; Yoneshima, Y.; Ambrose, H.; more...
    JCO Precision Oncology (2025)

    Fulltext@MSK | Save
  • Lung cancer and cardiovascular disease: Common pathophysiology and treatment-emergent toxicity
    Review

    El-Rayes, M.; Nardi Agmon, I.; Yu, C.; Osataphan, N.; Yu, H. A.; Hope, A.; Sacher, A.; Yu, A. F.; Abdel-Qadir, H.; Thavendiranathan, P.
    JACC: CardioOncology (2025)

    Fulltext@MSK | Save